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Ascites is a prominent feature of ovarian cancer and could serve as liquid biopsy to
assess the immune status of patients. Tumor-infiltrating T lymphocytes are correlated
with improved survival in ovarian cancer. To investigate whether immune cells in
ascites are associated with patient outcome, we analyzed the amount of dendritic
cell (DC) and T cell subsets in ascites from ovarian cancer patients diagnosed with
high-grade serous cancer (HGSC). Ascites was collected from 62 HGSC patients prior
to chemotherapy. Clinicopathological, histological and follow-up data from patients
were collected. Ascites-derived immune cells were isolated using density-gradient
centrifugation. The presence of myeloid DCs (BDCA-1+, BDCA-3+, CD16+), pDCs
(CD123+BDCA-2+), and T cells (CD4+, CD8+) was analyzed using flow cytometry.
Complete cytoreduction, response to primary treatment and chemosensitivity were
associated with improved patient outcome. In contrast, immune cells in ascites did
not significantly correlate with patient survival. However, we observed a trend toward
improved outcome for patients having low percentages of CD4+ T cells. Furthermore,
we assessed the expression of co-stimulatory and co-inhibitory molecules on T cells and
non-immune cells in 10 ascites samples. PD-1 was expressed by 30% of ascites-derived
T cells and PD-L1 by 50% of non-immune cells. However, the percentage of DC and
T cell subsets in ascites was not directly correlated to the survival of HGSC patients.
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INTRODUCTION
The majority of patients with epithelial ovarian cancer is diagnosed with advanced stage high-
grade serous cancer (HGSC), with a poor 5-year overall survival rate of just 25% (1, 2). Standard
treatment consists of cytoreductive surgery and platinum-based chemotherapy (3). Despite good
initial response rates, about 70% of the patients relapse within 18 months (3–5). Unfortunately,
over the last 30 years no significant improvement in survival is seen and, therefore, new treatment
options are needed (6).
Ovarian cancer is an immunogenic disease and the tumor microenvironment is infiltrated by
various immune cells that influence tumor progression and metastasis. The best studied immune
cell type in solid tumors are T cells. CD8+ cytotoxic T cells kill tumor cells when they recognize
an antigen that is presented by MHC class I. In ovarian cancer, tumor-infiltrating CD3+ and, more
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precisely, CD8+ T cells are associated with improved overall
survival in advanced stage HGSC, as are high CD8/CD4 ratios
(7–9).
In addition to T cells, DCs have been identified to infiltrate
tumor tissue (10). DCs sample antigens and display them in an
MHC-dependent context to T cells in the lymph node in order
to initiate a potent anti-tumor T cell response. In blood, two
main DC subsets exist that can be divided into myeloid DCs
(mDCs) and plasmacytoid DCs (pDCs). Based on the expression
of surface markers, mDCs can be further subdivided into BDCA-
1+ and BDCA-3+ mDCs (11). There is much debate about
the existence of a third, CD16 expressing mDC subset (12–14).
Each DC subset has its own characteristics and function. Hence,
the DCs present in the tumor microenvironment determine the
nature of the generated T cell response (15). Tumor infiltrating
DCs have been identified in many cancer types (16), but their
correlation with patient outcome is unclear.
The tumor-suppressive microenvironment in ovarian cancer
inhibits the function of effector T cells. Tumor cells down-
regulate MHC molecules to escape detection by T cells (17).
These tumor cells should be recognized and eliminated by
natural killer (NK) cells (18). However, in ovarian cancer,
NK cells are enriched for the less cytotoxic CD56brightCD16−
phenotype (19). In general, the link between infiltration of
NK cells and patient survival is not yet clear. Furthermore,
tumor cells attract and expand immunosuppressive cells, such
as M2 macrophages and regulatory T cells (TRegs) (20).
Depending on their activation, macrophages can acquire a M1
(classical activation) or M2 (alternative activation) phenotype.
Whereas M1 macrophages exert anti-tumorigenic functions, M2
macrophages promote tumor progression (21). Therefore, a high
M1/M2 ratio is associated with improved patient survival in
ovarian cancer. In contrast, a higher density of M2 macrophages
correlated with worse outcome (22). TRegs inhibit the function
of CD8+ T cells via cell-cell contact dependent mechanisms
and by secreting inhibitory cytokines, such as IL-10, thereby
limiting their tumor killing capacity (20). Tumor-infiltrating
TRegs are associated with worse patient outcome (23). The
immunosuppressive tumor microenvironment also promotes the
accumulation of immature DCs, which can induce tolerance
and expand the TReg pool (24). Thus, boosting the pre-existing
anti-tumor immune response by immunotherapy to overcome
the immunosuppressive mechanisms should be a promising
treatment strategy for ovarian cancer patients.
Immune infiltration into tumor tissue at baseline is an
important predictor for patient’s response to immunotherapy
(25, 26). Acquisition of tumor material can only be achieved
by invasive procedures. A prominent feature of advanced stage
HGSC is fluid accumulation (ascites) within the peritoneal cavity.
Ascites contains immune cells, such as macrophages, monocytes,
granulocytes, and lymphocytes and could be seen as a reflection
of the tumor microenvironment. The fluid can be obtained by
drainage, which is an easier and safer procedure. Therefore,
ascites could serve as liquid biopsy to assess the immune status
of ovarian cancer patients (27, 28). However, so far it remains
unclear whether immune cells in ascites can be correlated to
clinical patient outcome. To investigate whether the different DC
subsets correlate to T cell subsets, and whether these immune
cells can be linked to patient survival and clinical characteristics,
we analyzed the ascites of 62 HGSC patients.
METHODS
Patient Material
This study was carried out in accordance with the
recommendations of the “Dutch Code of Conduct for
Responsible Use of Human Tissue,” established by the
Federation of Dutch Medical Scientific Societies (Federa).
Ascites is considered as waste material and, therefore, no written
informed consent is needed. The protocol was approved by
the “Commissie Mensgebonden Onderzoek” (CMO Arnhem-
Nijmegen). Guidelines and regulations of the Radboudumc
for collection of human material were followed. Ascites was
collected from stage III or IV high-grade serous ovarian
cancer patients before start of the treatment. The outcome
of the cytoreductive surgery was defined as complete (no
macroscopically visible residual tumor), optimal (residual tumor
foci ≤1 cm) or suboptimal (residual tumor foci >1 cm). Staging
was based on the International Federation of Gynecology and
Obstetrics (FIGO) staging system. Data on adjuvant treatment,
CA-125 serum levels, recurrence and last date of follow-up were
collected. A good response to primary treatment was defined by a
normalized serum CA-125 level, a normal physical examination
and, if performed, a CT scan without evidence of recurrence.
Patients with recurrence within 6 months after completion of
chemotherapy were classified as having chemoresistant tumors.
Progression-free survival (PFS) was defined as period of time
(months) between last course of chemotherapy and recurrence.
Overall survival (OS) was defined as the period of time (months)
between the last course of chemotherapy and death or date of
last follow-up.
Isolation of Immune Cells From Ascites
Immune cells were isolated as described elsewhere (29). In
brief, ascites was filtered over a 100µm cell strainer (352360,
Corning, Falcon R©) and centrifuged for 15min at 1,500 rpm
and 4◦C. The cell pellet was resuspended in phosphate buffered
saline (PBS). Mononuclear cells were isolated using gradient
centrifugation with LymphoprepTM (1114544, Axis-Shield).
Isolated immune cells were cryopreserved in a dimethyl
sulfoxide (DMSO, 06800001, WAK-Chemie)-containing
medium.
Flow Cytometry
Ascites-derived mononuclear cells were blocked for 10min
with 50 µl PBA/2% FcR blocking reagent (130-090-532,
Miltenyi). Subsequently, cells were incubated for 30min with
directly conjugated antibodies. The cells were washed with
PBA and analyzed. Different panels were used for immune cell
phenotyping. T cells were identified using antibodies against
CD3, CD4, and CD8. mDCs were identified using antibodies
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against CD45, CD14, CD16, CD19, BDCA-1 (CD1c), and BDCA-
3 (CD141). For pDCs, antibodies against CD123 and BDCA-
2 (CD303) were used. Immune checkpoint expression was
analyzed on CD3+ T cells and CD45- cells.
Antibodies
The following antibodies were used: CD3-FITC (1:25, 555339,
BD Pharmingen), CD3-BV510 (1:25, 563083, BD), CD4-APC-
Cy7 (1:20, 300518, BioLegend), CD8-PerCP (1:20, 345774, BD),
CD14-APC-Cy7 (1:20, 557831, BD Pharmingen), CD16-PE-Cy7
(1:200, 335823, BD), CD19-PerCP (1:2.5, 345778, BD), CD40-
PE (1:10, IM19360U, Beckman), CD40-L-PE (1:10, IM2216U,
Beckman), CD45-V450 (1:50, 560367, BD), CD45-FITC (1:10,
130-080-202, Miltenyi Biotec), CD80-PE-Cy7 (1:50, 561135,
BD), CD86-PE (1:10, 555658, BD) CD123-FITC (1:10, 130-090-
897, Miltenyi Biotec), BDCA-1-PE (1:10, 130-090-508, Miltenyi
Biotec), BDCA-2-APC (1:10, 130-090-905, Miltenyi Biotec),
BDCA-3-APC (1:10, 130-090-907, Miltenyi Biotec), CTLA-4-PE
(1:5, 555853, BD), HLA-DR-BV510 (1:25, 563083, BD), ICOS-
PerCP-Cy5.5 (1:10, 562833, BD), ICOS-L-PerCP (1:5, FAB165C,
R&D Systems), PD-1-PerCP-Cy5.5 (1:10, 561273, BD), PD-L1-
PE-Cy7 (1:10, 558017, BD).
Statistical Analysis
Comparisons between DC and T cell subsets were made using
Pearson’s r-test on Log-transformed data. The Mann-Whitney
U-test was used for comparisons between clinicopathological
characteristics and DC and T cell subset percentages.
Correlations between immune cell populations and clinical
characteristics were done using univariate Cox regression
analysis. Correlations between immune cell populations and
survival were analyzed using Cox regression and Kaplan-Meier
survival curves (log-rank test). All p-values were considered
significant when p < 0.05. SPSS 22.0 software was used for
statistical analyses.
RESULTS
Patient Characteristics
Ascites from 62 ovarian cancer patients was collected prior to any
chemotherapy treatment via ascites drainage or during primary
surgery (Table 1). All patients were diagnosed with HGSC. Out
of 62 patients, 52 were diagnosed with FIGO stage III and 10 with
stage IV disease. The median age at diagnosis was 64 years (range
42–80 years). One patient was treated with chemotherapy only
and one patient underwent cytoreductive surgery only. Twenty
two patients underwent a primary debulking, followed by six
courses of adjuvant chemotherapy. The remaining 39 patients
received three courses of neo-adjuvant chemotherapy, followed
by interval debulking and another three courses of adjuvant
chemotherapy. Complete or optimal (≤1 cm residual tumor foci)
cytoreduction was achieved in 26 and 28 patients, respectively,
whereas 7 patients had a suboptimal (>1 cm residual tumor
foci) debulking. The majority of patients received combination
chemotherapy, consisting of taxol and platinum (cisplatin,
carboplatin), and six patients received carboplatin monotherapy.
A good response to primary treatment was observed in 38
TABLE 1 | Clinicopathological characteristics of high-grade serous ovarian cancer
patients.
N (62) %
Median age (range) 64 (42–80)
FIGO STAGE
III 52 84
IV 10 16
SURGERY
Primary cytoreduction 22 35
Secondary cytoreduction 39 63
No cytoreduction 1 2
OUTCOME SURGERY
Complete 26 42
Optimal (≤1 cm) 28 46
Suboptimal (>1 cm) 7 12
CHEMOTHERAPY
Taxol/Platinum 56 90
Non-taxol 5 8
No chemotherapy 1 2
RESPONSE TO PRIMARY TREATMENT
Responder 38 63
Non-responder 22 37
IGO, Fédération Internationale de Gynécologie Obstétrique.
patients. Median PFS and OS was 7 months (range 0–95) and 21
months (range 1–99), respectively.
mDCs, pDCs, and T Cells Are Present in
Ascites
DC and T cell subsets in ascites were analyzed using flow
cytometry. Due to limited cell numbers in some samples,
mDCs were measured in 56 samples and pDCs and T cells in
62 ascites samples. BDCA-1+, BDCA-3+, and CD16+ mDCs
were analyzed in the CD45+CD14− cell population (Table 2,
Figure 1A). pDCs were identified by co-expression of CD123
and BDCA-2 (Figure 1B). BDCA-1+ and BDCA-3+ mDCs
were detected in 91% (51/56) and 96% (54/56) of ascites
samples, respectively. CD16+ mDCs and pDCs were present
in 100% (56/56 and 62/62) of patient samples. The median
percentage of the different DC subsets in ascites was 1.8%
for BDCA-1+ mDCs (range 0.0–21.2%), 0.9% for BDCA-3+
mDCs (range 0.0–4.9%), 2.8% for CD16+ mDCs (range 0.4–
21.4%), and 2.1% for pDCs (range 0.1–8.8%) (Figure 1D). T
cells were detected in 100% (62/62) of ascites samples. The
median percentage of T cell subsets in the CD3+ cell population
was 45.5% for CD4+ T cells (range 2.0–78.0%), containing
T helper cells and TRegs, and 33.0% for CD8
+ cytotoxic T
cells (range 1.0–65.0%) (Figures 1C,E). The correlation between
DC and T cell subsets was investigated by calculating the
Pearson correlation coefficient. There was no correlation between
BDCA-1+, BDCA-3+, and CD16+ mDCs and the different
T cell subsets. In contrast, percentages of pDCs positively
correlated with higher percentages of CD4+ T cells (r = 0.348,
p= 0.048).
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TABLE 2 | Markers used for the identification of mDCs, pDCs and T cells by flowcytometry.
Cell type Markers Function
BDCA-1+ mDCs CD45+CD14−BDCA-1+ Directing polarization of CD4+ T helper cells to Th1, Th2 or Th17 phenotype
BDCA-3+ mDCs CD45+CD14−BDCA-3+ Polarization of CD4+ T helper cells to Th1 phenotype; Cross-presentation of antigens
to CD8+ T cells
CD16+ mDCs CD45+CD14−CD16+ Antibody dependent cellular cytotoxicity;
pDCs CD123+BDCA-2+ Secretion of type I interferons; induction of T regulatory cells
CD4+ T cells CD3+CD4+ CD4+ T helper cells aid to initiate a proper immune response; CD4+ T regulatory
cells dampen the immune response
CD8+ T cells CD3+CD8+ Cytotoxic T cells; kill infected or cancerous cells
FIGURE 1 | T cell and DC subsets in ascites. DC en T cells subsets were measured in ascites of 62 high-grade serous ovarian cancer patients using flowcytometry.
(A) Gating strategy for myeloid dendritic cells. Lymphocytes were excluded based on FSC/SSC. BDCA-1+, BDCA-3+, and CD16+ mDCs were gated in the
CD45+CD14− cell population. (B) pDCs were identified based on co-expression of BDCA-2 and CD123. (C) T cell gating strategy. CD4+ and CD8+ T cells were
gated in the CD3+ lymphocyte population. (D) Percentage of DC subsets in ascites. (E) Percentage of T cells in ascites. Red line indicates mean.
PFS and OS Are Independent of the
Percentage of DC and T Cell Subsets in
Ascites
We did not find a significant difference in the percentage
of DC and T cell subsets between complete vs. incomplete
cytoreduction, responders vs. non-responders, and
chemosensitive vs. chemoresistant tumors (Table S1). Clinical
characteristics significantly correlated with patient outcome.
Patients with complete cytoreduction, a good response to
primary treatment and chemo sensitive primary tumors had
improved PFS (Figure 2A) and OS (Figure 3A, Table S2).
Furthermore, based on the median, patients were stratified
as having low or high percentages of immune cells. There
was no significant difference in PFS (Figures 2B,C) and OS
(Figures 3B,C) for patients with low or high percentages of DC
and T cell subsets in ascites, although we observed a trend toward
improved PFS and OS for patients having low percentages of
CD4+ T cells in ascites.
Trend Toward Improved PFS and OS for
Patients With High Percentages of CD16+
mDCs and Low Percentages of CD4+ T
Cells
Even though the percentage of DC and T cell subsets did not
significantly correlate with patient outcome, long PFS and OS
were more likely to occur in patients with a low percentage
of CD4+ T cells and a high percentage of CD16+ mDCs
(Table S3). For patients with a low percentage of CD4+ T cells,
the PFS rate at 18 months was 30.0% and the OS rate at 60
months was 17.0%, in contrast to 13.0 and 7.0%, respectively, for
patients with a high percentage of CD4+ T cells. Furthermore,
26.0% of patients with a high percentage of CD16+ mDCs
were free of recurrence after 18 months and 19.0% alive at 60
months, whereas the probability of PFS and OS for patients
with a low percentage of CD16+ mDCs was 19.0 and 7.0%,
respectively.
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FIGURE 2 | Kaplan-Meier curves for progression-free survival of HGSC patients. (A) Progression-free survival curves for clinical characteristics. (B) Progression-free
survival for patients stratified as having low or high percentages of immune cells in ascites. Cut-off values based on median. BDCA-1: 1.8%; BDCA-3: 0.9%; CD16:
2.8%; pDC: 2.1%; CD4: 45.5%; CD8: 33.0%; (C) Progression-free survival for patients stratified as having low or high CD4/CD8 ratios. Cut-off at 1.3, based on
population median. P-values for significant differences are given. P-values < 0.05 were considered significant.
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FIGURE 3 | Kaplan-Meier curves for overall survival of HGSC patients. (A) Overall survival curves for clinical characteristics. (B) Overall survival for patients stratified as
having low or high percentages of immune cells in ascites. Cut-off values based on median. BDCA-1: 1.8%; BDCA-3: 0.9%; CD16: 2.8%; pDC: 2.1%; CD4: 45.5%;
CD8: 33.0%; (C) Overall survival for patients stratified as having low or high CD4/CD8 ratios. Cut-off at 1.3, based on population median. P-values for significant
differences are given. P-values < 0.05 were considered significant.
Frontiers in Immunology | www.frontiersin.org 6 January 2019 | Volume 9 | Article 3156
Wefers et al. Immune Cells in Ascites
FIGURE 4 | Expression of MHC, co-stimulatory and co-inhibitory molecules on CD3+ T cells and non-immune cells in ascites. Flow cytometry gating of immune
checkpoint and MHC on (A) CD3+ positive cells and (C) CD45− cells. Gray line represents control; black line represents CD3+ T cells or CD45− cells. (B) CD3+ T
cells and (D) CD45− cells positive for co-stimulatory, co-inhibitory, and MHC molecules. Red lines indicate mean.
Ascites-Derived T Cells Are Positive for the
Inhibitory Checkpoint PD-1
Since the percentage of CD4+ and CD8+ T cells was not
directly correlated to clinical characteristics of HGSC patients,
we investigated the activation status of ascites-derived T
cells. The expression of immune checkpoint markers was
investigated in 10 ascites samples, being 6 responders and
4 non-responders, of which enough cells were available for
further analysis. Checkpoint marker expression was analyzed on
CD3+ T cells (Figures 4A,B) and on the CD45− cell population
(Figures 4C,D).
The co-stimulatory molecule CD28 was detected on 81.6% of
T cells, whereas CD40L and ICOS were expressed on a minority
of cells, 4.8 and 8.1%, respectively. About 21.4% of the T cells were
positive for the activation marker HLA-DR. The co-inhibitory
molecule CTLA-4 was barely present on T cells. In contrast, the
mean of PD-1 expressing cells was 30.7%, ranging from 14 to
51.5% in the ascites samples.
We also analyzed the expression of the corresponding ligands
and receptors on the CD45− cell population in ascites. The
co-stimulatory molecule CD28 competes with the co-inhibitory
molecule CTLA-4 for binding to CD80 and CD86. About 32.0%
of non-immune cells expressed the co-stimulatory molecule
CD80, whereas CD86 is only expressed by 5.4%. The ligand for
the ICOS receptor, ICOS-L, was present on 3.8% of non-immune
cells. CD40, which binds to CD40L, was detected on 22.4.0% and
HLA-ABC, important for antigen presentation to CD8+ T cells,
was detected on 44.1% of CD45− cells. On average, 48.8% of non-
immune cells were positive for the ligand for the co-inhibitory
molecule PD-1, PD-L1, ranging from 9.1 to 72.3%.
DISCUSSION
The aim of this study was to investigate whether themain DC and
T cell subsets in ascites are correlated to clinical characteristics or
patient outcome. We detected DCs and T cells in a majority of
ascites samples. However, survival of ovarian cancer patients was
largely independent of the amount of these cells in ascites.
DC subsets were analyzed in the CD45+CD14− cell
population. The rationale to study DCs is that each subset
has its own characteristics and functions. Whereas, BDCA-1+
mDCs direct the polarization of CD4+ T helper cells, BDCA-
3+ DCs are potent at cross-presenting antigens to CD8+ T
cells and, therefore, have an important role in inducing T
cell responses against tumor cells (11). There is much debate
about whether CD16+ mDCs are actual DCs or non-classical
Frontiers in Immunology | www.frontiersin.org 7 January 2019 | Volume 9 | Article 3156
Wefers et al. Immune Cells in Ascites
monocytes. Nevertheless, these cells are potent in antibody-
dependent cellular cytotoxicity and induce T cell proliferation
and we observed a trend toward improved survival in patients
with high percentages of CD16+ mDCs (13). However, we did
not find a correlation between mDC subsets and CD4+ or
CD8+ T cells. pDCs have a strong pro-inflammatory function
by secreting type I IFNs in response to viral infections (11).
On the other hand, they produce indoleamine 2,3-dioxygenase
(IDO) and induce TRegs, thereby, dampening the immune system
(11, 20). We found a positive correlation between pDCs and
CD4+ T cells in ascites of HGSC patients. We additionally
observed a trend toward improved PFS and OS in patients with
low percentages of CD4+ T cells. Patients with a high percentage
of CD4+ T cells had worse clinical outcome, pointing toward
a regulatory phenotype of these cells. However, there was no
significant link between the percentage of DC and T cell subsets
in ascites and survival of HGSC patients. In contrast, clinical
characteristics, such as complete cytoreduction, good response to
primary treatment, and chemosensitivity correlated to improved
patient outcome.
Ascites is an immunosuppressive milieu, which could explain
why immune cells in ascites are not correlated to patient
outcome. We as well as others, showed that ascites interferes
with T cell function. This inhibition is mediated by various
factors, such as lipids, chemokines, and by the presence of
regulatory immune cells in ascites fluid (30–33). For example,
Landskron et al. characterized the T cell population in ascites and
peripheral blood of ovarian cancer patients. They demonstrated
that activated cytokine-secreting TRegs were enriched in ascites
(34). Furthermore, ascites contains high levels of IL-10, which
can stimulate the expansion of the TReg population and inhibits
CD8+ T cell function (35). Additionally, ascites affects the
polarization of macrophages. IL-6 and IL-10 in ascites promote
the differentiation of macrophages into the immunosuppressive
M2 phenotype, which stimulates tumor cell proliferation and
suppresses the effector functions of cytotoxic T cells (36, 37).
We also detected that 30% of the T cells in ovarian cancer
ascites were positive for PD-1. The ligand PD-L1 is present on
50% of the CD45− population, which contains tumor cells. The
PD-1/PD-L1 axis could be a mechanism that interferes with
the cytotoxic activity of CD8+ T cells in ascites. However, it
remains to be elucidated whether PD-1 expression is a marker
for exhaustion or activation. Next to T cells, ascites fluid may
also inhibit the function of DCs. Recently, ascites fluid was
shown to interfere with the activation of in vitro generated
monocyte-derived DCs. Ascites reduced the expression of the co-
stimulatory molecule CD86 and decreased the T cell stimulatory
capacity (38). Hence, ovarian cancer ascites may effectively limit
the anti-tumor immune response and, therefore, ascites-derived
immune cells might not correlate with patient outcome. In the
future, it might be important to assess the activation status of DC
and T cell subsets in ovarian cancer ascites.
So far, only a few research groups have investigated the effect
of immune cells in ascites on the outcome of ovarian cancer
patients. These studies found contradicting results and are partly
in contrast to our own findings. For example, Giuntoli et al.
showed that the ratio of CD4/CD8T cells in ovarian cancer
ascites is correlated to patient outcome. They demonstrated that
patients with low CD4/8 ratios had improved survival (39), a
finding we could not confirm. In contrast, Lieber et al. found
no correlation of CD4+ or CD8+ T cells with patient outcome,
but identified memory T cells to confer survival advantage in
HGSC patients (40). Although not statistically significant, we
observed a trend toward improved outcome of patients with low
percentages of CD4+ T cells. The group of Bamias et al. found
that CD3+CD56+ cells in ascites were associated with platinum
resistance (41), whereas we did not observe a correlation of
DC or T cell subsets with platinum resistance. Hoogstad-van
Evert et al. detected no association of CD3+ T cells with patient
outcome, but found NK cells in ovarian cancer ascites to be
correlated with improved survival (42). These studies used a
limited number of samples or were composed of a heterogeneous
patient population, including different epithelial ovarian cancer
subtypes and material from before and after therapy. In this
study, we tested the ascites of a well-defined group of patients,
all being chemotherapy naïve and with diagnosed advanced-stage
HGSC.
In summary, we showed that DC and T cell subsets in ascites,
in contrast to tumor infiltrating T cells, did not correlate with
clinical characteristics or survival of HGSC patients. Future
research needs to directly compare the immune infiltration in
ascites and primary tumor tissue to draw conclusions on the
immune environment in these two compartments. Furthermore,
research on ascites would benefit from lager patient cohorts,
as this would allow for more advanced statistical analysis.
This requires the systematic biobanking of ascites, which is
currently not done. Finally, homogenous patient cohorts are
crucial to reliably correlate immune cells in ascites with patient
outcome. This study serves as starting point for future research
investigating the immune infiltrate in ovarian cancer ascites.
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